Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Co's existing focus is on the development of product candidates to treat COVID-19, hepatitis C virus (HCV), dengue and respiratory syncytial virus. Co.'s product candidate for the treatment of COVID-19 is bemnifosbuvir. For the treatment of chronic HCV infection, Co. is developing a combination of bemnifosbuvir and ruzasvir, an investigational nonstructural protein 5A inhibitor. Co. is developing AT-752, an oral, purine nucleotide prodrug for the treatment of dengue. We show 13 historical shares outstanding datapoints in our coverage of AVIR's shares outstanding history.
Understanding the changing numbers of AVIR shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AVIR versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AVIR by allowing them to research AVIR shares outstanding history
as well as any other stock in our coverage universe. |
Free AVIR Email Alerts:
Video: Shares Outstanding Importance
